Background: Although patients (pts) with hormone receptor-positive (HR+)/HER2-negative breast cancer (BC) frequently experience disease response to neoadjuvant therapy, fewer than 10% achieve a ...

1Division of Precision Medicine, Department of Medicine, New York University Grossman School of Medicine, New York, New York. 2Department of Pathology, New York University Grossman School of Medicine, ...

Abstract. Most definitions of cancer broadly conform to the current NCI definition: “Cancer is a disease in which some of the body's cells grow uncontrollably and spread to other parts of the body.” ...

Mol Cancer Ther (2023) 22 (12_Supplement): PR008.

You do not currently have access to this content.

Cancer Res (2025) 85 (8_Supplement_2): CT012. Novel immune strategies are needed to improve outcomes in patients (pts) with microsatellite-stable metastatic colorectal cancer (MSS mCRC). Our ...

B7-H3 (CD276), an immune checkpoint member of the B7/CD28 family, is widely expressed in multiple cancers and is associated with poor prognosis. YL201 is a novel B7-H3-targeting antibody-drug ...

Cancer Res (2025) 85 (8_Supplement_2): CT112.

Cancer Res (2025) 85 (8_Supplement_2): ND07. FAP (Fibroblast Activation Protein) is expressed on cancer-associated fibroblasts (CAFs) and is a highly attractive target in Radioligand Therapy (RLT) due ...

EGFR and HER3 are receptor tyrosine kinases that are highly expressed in multiple epithelial tumors. EGFR point mutations and small insertions within the kinase domain are common in lung cancer. HER3 ...

Abstract. Ladiratuzumab vedotin (LV, SGN-LIV1A) is an antibody-drug conjugate directed against the LIV-1 protein that is currently under investigation for treatment in metastatic breast cancer. This ...